Indivior PLC (NASDAQ:INDV) Receives Average Rating of “Buy” from Brokerages

Indivior PLC (NASDAQ:INDV) has been given a consensus recommendation of “Buy” by the nine ratings firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $32.7143.

Several research analysts have recently issued reports on INDV shares. Morgan Stanley reiterated an “overweight” rating and issued a $36.00 price objective on shares of Indivior in a report on Wednesday, December 3rd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Indivior in a research note on Friday, October 31st. Zacks Research raised Indivior from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 3rd. Northland Securities set a $40.00 price objective on Indivior in a report on Friday, October 31st. Finally, HC Wainwright lifted their target price on Indivior from $28.00 to $35.00 and gave the stock a “buy” rating in a report on Thursday, October 30th.

Institutional Trading of Indivior

A number of hedge funds and other institutional investors have recently made changes to their positions in INDV. CWM LLC acquired a new position in Indivior in the third quarter worth approximately $25,000. Quarry LP bought a new stake in shares of Indivior during the 3rd quarter worth $26,000. Raymond James Financial Inc. acquired a new position in shares of Indivior in the 2nd quarter worth $26,000. Plato Investment Management Ltd acquired a new stake in shares of Indivior during the third quarter worth $52,000. Finally, Blue Trust Inc. purchased a new stake in shares of Indivior during the third quarter valued at $99,000. 60.33% of the stock is currently owned by institutional investors.

Indivior Price Performance

NASDAQ:INDV opened at $35.54 on Friday. Indivior has a 1 year low of $7.62 and a 1 year high of $38.00. The business has a fifty day moving average of $30.72 and a 200-day moving average of $23.40.

Indivior (NASDAQ:INDV) last posted its quarterly earnings data on Thursday, October 30th. The company reported $0.72 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.34. The business had revenue of $314.00 million during the quarter, compared to the consensus estimate of $257.66 million. Indivior had a net margin of 9.83% and a negative return on equity of 90.79%. Analysts forecast that Indivior will post 1.22 earnings per share for the current year.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.